Afatinib tablets 40mg/tablet, 30 tablets/box

Medication Safety Tips

Use this product according to its instructions, medical advice, and your health needs. Shipping is arranged after payment once the order meets dispatch requirements.

Contraindications

Warnings and Precautions
• Diarrhea: Diarrhea can lead to dehydration and renal failure. Suspend LuciAfa for severe and prolonged diarrhea with no response to anti-diarrheal medication.
• Bullous and exfoliative dermatoses: Severe bullous, blistering, and exfoliative lesions occurred in 0.2% of patients. Discontinuation due to life-threatening skin reaction. For severe and prolonged skin reactions, discontinue LuciAfa.
• Interstitial lung disease (ILD): occurs in 1.6% of patients. Discontinue LuciAfa in case of exacerbation or worsening of pulmonary symptoms. If ILD is diagnosed, discontinue use of LuciAfa.
• Hepatotoxicity: Fatal liver injury occurred in 0.2% of patients. Regular liver examinations are performed. The examination found that the liver disease worsened or worsened, and LuciAfa was suspended or discontinued.
• Gastrointestinal perforation: occurred in 0.2% of patients. Patients with gastrointestinal perforation should permanently discontinue LuciAfa.
• Keratitis: 0.7% of patients. Suspend LuciAfa for keratitis assessment. Suspend or discontinue LuciAfa for diagnosed ulcerative keratitis.
• Embryo-fetal toxicity: may cause harm to the fetus when taken by a pregnant woman. Inform pregnant women and women of childbearing potential of the potential risks to the fetus and use effective contraception.

Medication risks

Adverse Reactions
The most common adverse reactions (≥ 20%) are diarrhea, rash/acne-like dermatitis, stomatitis, thyroiditis, dry skin, decreased appetite, nausea, vomiting, itching.